TY - JOUR
T1 - Safety and Efficacy of Peripheral Embolization with EASYX Liquid Embolic Agent
T2 - A Multicenter Prospective Study
AU - Sapoval, Marc
AU - Vidal, Vincent
AU - Déan, Carole
AU - Del Giudice, Costantino
AU - Tradi, Farouk
AU - Chevallier, Olivier
AU - Charles-Nelson, Anaïs
AU - Pellerin, Oliver
AU - Loffroy, Romaric
N1 - Funding Information:
The study was funded by a grant from Antia Therapeutics and Qmedics. The study was sponsored by Assistance Publique-Hôpitaux de Paris ( AP-HP , Délégation à la Recherche Clinique et à l’Innovation).
Funding Information:
The study was funded by a grant from Antia Therapeutics and Qmedics. The study was sponsored by Assistance Publique-H?pitaux de Paris (AP-HP, D?l?gation ? la Recherche Clinique et ? l'Innovation).
Publisher Copyright:
© 2021 SIR
PY - 2021/8
Y1 - 2021/8
N2 - Purpose: To evaluate the clinical safety and efficacy of EASYX, a new nonadhesive precipitating liquid embolic agent based on a polyvinyl alcohol ether polymer labeled with iodine molecules, for peripheral embolization. Materials and Methods: This open-label prospective multicenter study was conducted on 50 consecutive patients treated with embolization using EASYX in 3 academic hospitals from April 2018 to July 2019. Indications for embolization were symptomatic varicocele (n = 15), type II endoleak (n = 8), acute hemorrhage (n = 16), portal vein embolization (PVE; n = 9), or angiomyolipoma (AML; n = 2). Patient characteristics, technical and clinical success rates, pain at injection, and satisfaction of the interventional radiologists were assessed. Follow-up imaging was performed using ultrasound for varicoceles (at 1 month) and computed tomography (CT) for the other indications (at 3 or 6 months). Results: The immediate technical success rate was 98%. The clinical success rates were 100% for acute hemorrhage and type II endoleaks, 89% for PVE, 86% for varicoceles, and 50% for AMLs. Patients who underwent PVE showed significant hypertrophy of the future liver remnant at follow-up (P < .001), and 55.6% of patients proceeded to hepatectomy. The absence of artifacts on imaging allowed improved monitoring of the aneurysmal sac in patients with type II endoleaks. The satisfaction rate of the interventional radiologists was >90% for 5 of 7 items. Conclusions: EASYX as a novel copolymer liquid embolic agent was safe and efficient for peripheral embolization. The absence of tantalum allowed reduced CT artifacts on imaging follow-up, which was especially useful in patients with type II endoleaks.
AB - Purpose: To evaluate the clinical safety and efficacy of EASYX, a new nonadhesive precipitating liquid embolic agent based on a polyvinyl alcohol ether polymer labeled with iodine molecules, for peripheral embolization. Materials and Methods: This open-label prospective multicenter study was conducted on 50 consecutive patients treated with embolization using EASYX in 3 academic hospitals from April 2018 to July 2019. Indications for embolization were symptomatic varicocele (n = 15), type II endoleak (n = 8), acute hemorrhage (n = 16), portal vein embolization (PVE; n = 9), or angiomyolipoma (AML; n = 2). Patient characteristics, technical and clinical success rates, pain at injection, and satisfaction of the interventional radiologists were assessed. Follow-up imaging was performed using ultrasound for varicoceles (at 1 month) and computed tomography (CT) for the other indications (at 3 or 6 months). Results: The immediate technical success rate was 98%. The clinical success rates were 100% for acute hemorrhage and type II endoleaks, 89% for PVE, 86% for varicoceles, and 50% for AMLs. Patients who underwent PVE showed significant hypertrophy of the future liver remnant at follow-up (P < .001), and 55.6% of patients proceeded to hepatectomy. The absence of artifacts on imaging allowed improved monitoring of the aneurysmal sac in patients with type II endoleaks. The satisfaction rate of the interventional radiologists was >90% for 5 of 7 items. Conclusions: EASYX as a novel copolymer liquid embolic agent was safe and efficient for peripheral embolization. The absence of tantalum allowed reduced CT artifacts on imaging follow-up, which was especially useful in patients with type II endoleaks.
UR - http://www.scopus.com/inward/record.url?scp=85109437145&partnerID=8YFLogxK
U2 - 10.1016/j.jvir.2021.05.014
DO - 10.1016/j.jvir.2021.05.014
M3 - Article
C2 - 34098072
AN - SCOPUS:85109437145
VL - 32
SP - 1136
EP - 1143
JO - Journal of Vascular and Interventional Radiology
JF - Journal of Vascular and Interventional Radiology
SN - 1051-0443
IS - 8
ER -